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ABSTRACT: The traﬃcking chaperone PDE6D (also referred to as PDEδ)
has been nominated as a surrogate target for K-Ras4B (hereafter K-Ras). Arl2-
assisted unloading of K-Ras from PDE6D in the perinuclear area is signiﬁcant
for correct K-Ras localization and therefore activity. However, the unloading
mechanism also leads to the undesired ejection of PDE6D inhibitors. To
counteract ejection, others have recently optimized inhibitors for picomolar
aﬃnities; however, cell penetration generally seems to remain an issue. To
increase resilience against ejection, we engineered a “chemical spring” into
prenyl-binding pocket inhibitors of PDE6D. Furthermore, cell penetration
was improved by attaching a cell-penetration group, allowing us to arrive at micromolar in cellulo potencies in the ﬁrst
generation. Our model compounds, Deltaﬂexin-1 and -2, selectively disrupt K-Ras, but not H-Ras membrane organization. This
selectivity proﬁle is reﬂected in the antiproliferative activity on colorectal and breast cancer cells, as well as the ability to block
stemness traits of lung and breast cancer cells. While our current model compounds still have a low in vitro potency, we expect
that our modular and simple inhibitor redesign could signiﬁcantly advance the development of pharmacologically more potent
compounds against PDE6D and related targets, such as UNC119 in the future.
■ INTRODUCTION
The oncogene Ras is one of the best-established cancer targets
without an approved inhibitor. Ras drug development eﬀorts in
the 1990s were thwarted by the failure of farnesyltransferase
inhibitors (FTI) in clinical trials.1 At that time, it was
underappreciated that the highly mutated K-Ras and N-Ras
can be alternatively prenylated by geranylgeranyltransferase I,
reinstating Ras plasma membrane localization and thus activity,
even in the presence of FTIs.2
Recently, there has been a resurgence in Ras drug develop-
ment, with both direct and indirect targeting approaches.3 The
Shokat group has pioneered direct, covalent inhibitors that
target a switch II pocket in GDP-bound K-RasG12C.4 Eﬃcacy
of these compounds relies on the intrinsic GTPase activity of
that mutant and trapping of an inhibitor-bound inactive state.5
Therefore, inhibitor eﬃcacy can be increased by enriching the
cellular pool of GDP-bound K-RasG12C, such as through
inhibition of upstream receptor tyrosine kinases (e.g., EGFR,
FGFR1, AXL) or Ras/Sos1 inhibitors, such as BAY-293.6
Switch II pocket inhibitors have rapidly evolved7 and are now
in clinical trials.8 Thus, it is for the ﬁrst time possible to assess the
eﬀect of selectively targeting a driver oncogene. While lung
cancer patient data are encouraging, the durable responses and
adaptive immunity that is seen in animal models are striking and
may indicate the signiﬁcance of K-Ras inhibition for curing
cancer.
Given that other mutant K-Ras alleles are not targeted by
these covalent inhibitors, diﬀerent K-Ras inhibition approaches
are still needed. Therefore, other noncovalent Ras binders with
inhibitory potential remain interesting. They were typically
discovered by computational approaches, such as the Kobe-
compounds or pyrazolopyrimidine allosteric compounds, which
block Ras-eﬀector interaction and have micromolar cellular
potencies.9,10
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The indirect target PDE6D is a traﬃcking chaperone of
farnesylated proteins, which may suggest that its inhibition
aﬀects the same clients as inhibition of farnesyltransferase.
However, PDE6D has a diﬀerent client proﬁle than farnesyl-
transferase, as it cannot facilitate intracellular diﬀusion of
proteins that are also palmitoylated.11,12 Moreover, PDE6D has
the potential to accommodate geranyl-geranylated clients.12
Thus, PDE6D inhibition selectively aﬀects K-Ras4B (hereafter
Figure 1. Newly designed inhibitors compete with K-Ras for PDE6D in vitro. (A) Design of Deltaﬂexin compounds, where in the ﬁrst generation a
generic heterocycle “top”was linked via a ﬂexible hexyl “spring” to the protected phosphodiester “bottom”. (B) SPR data of Deltarasin and compounds
15 (Deltaﬂexin-1), 14 and 17; n = 3. N-terminal avi-tagged K-RasFMe was captured on a neutravidin sensor chip and the inhibitory activity of
compounds for the PDE6D/avi-K-RasFMe interaction was measured. (C) Dose−response curve of Deltarasin and compounds 15 (Deltaﬂexin-1), 14
and 17 from the SPR data. (D) Docked structure of Deltaﬂexin-1 into the crystal structure of PDE6D in the open (cyan, PDB code 4JV8) and Arl2-
GTP-bound, closed state (green, PDB code 1KSJ). Right shows details of PDE6D (open) residues in proximity of docked Deltaﬂexin-1.
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K-Ras) traﬃcking but has much less eﬀect on traﬃcking of dual-
palmitoylated H-Ras.11,13
In order to relay signaling, K-Ras needs to be localized
predominantly to the plasma membrane. This requires energy-
dependent vesicular transport of K-Ras to the plasma membrane
from the recycling endosome, where it is collected after PDE6D-
assisted diﬀusion from internal cellular membranes.11,13
Unloading of K-Ras from PDE6D in the perinuclear compart-
ment requires the binding of GTP-Arl2 to PDE6D, which results
in an allosteric conformational change in PDE6D that eﬀectively
releases its cargo.14 Unfortunately, this ejection mechanism also
applies to the ﬁrst two generations of PDE6D inhibitors
Deltarasin15 and Deltazinone,16 developed by the Waldmann
group. Only their third generation of PDE6D inhibitors, the
Deltasonamides, can largely withstand Arl2-mediated ejection,
as they were highly optimized for sub-nanomolar aﬃnity.
However, these compounds have a low partitioning coeﬃcient,
suggesting low cell penetration.17 Unfortunately, this theme of
micromolar cellular potency, despite nanomolar aﬃnity to the
target in vitro, also continues with more recent PDE6D
inhibitors that emerged through substantial fragment-based
discovery and structure-based virtual screening eﬀorts by the
Xiong and Sheng groups.18
In order to advance PDE6D inhibitor development, it may
therefore be necessary to change the overall concept, as the
discovery of various chemotypes with high in vitro aﬃnity has
been well demonstrated. We here present Deltaﬂexins, which
have only micromolar in vitro, yet also micromolar in cellulo
potencies. We have overcome the approximately 1000-fold in
vitro to in cellulo potency gap, by employing an innovative
compound engineering approach.
■ RESULTS AND DISCUSSION
Generic Design of PDE6D Inhibitors with a Flexible
Hexyl-Linker and Cleavable Cell Penetration Group. In
order to improve the resilience of inhibitors against Arl2-
mediated ejection from the PDE6D prenyl-binding pocket, a
ﬂexible hexyl linker that was envisaged to act like a buﬀering
spring, was attached to a moiety that would provide major
contacts to the “top” of the pocket. The design was completed by
a simple phosphodiester “bottom” moiety, which was protected
with a previously developed cell penetration group that was
tunable for pharmacological stability.19,20 In our ﬁrst-generation
model compound, Deltaﬂexin-1 (15), the generic, heterocylic
coumarin was chosen as “top”-moiety, as it would allow for H-
bonding and π-stacking (Figure 1A). In addition, a panel of
seven control compounds was synthesized that allowed us to
assess the contribution of each of the design elements (Figures
1A, S1A).
In order to validate the inhibitory activity of the compounds
on the PDE6D/K-Ras interaction, we established a surface
plasmon resonance (SPR) assay. Farnesylated and carboxyme-
thylated K-Ras (K-RasFMe) were captured on the sensor chip
surface via an avi-tag, and the binding of PDE6D was measured
(Kd PDE6D/avi-K-RasFMe = 3.6± 0.1 μM) (Figure S1B, Table
1). Deltaﬂexin-1 (15) bound with a surprisingly good, low
micromolar Kd that was only 2.6-fold higher than what we
determined for Deltarasin (Figure 1B,C, Table 1). This was
encouraging given that this was the ﬁrst generation of
compounds. Importantly, the control compound 17 with a
“stiﬀ”, methyl cyclohexylmethyl linker had essentially the same
aﬃnity to PDE6D as compound 15 and therefore represented an
excellent control for testing the signiﬁcance of the ﬂexible hexyl
linker later on in cells (Figure 1C, Table 1). The relatively
hydrophobic 14, which lacked the cell-penetration bottom-
moiety exhibited a reduced binding activity (Figure 1C, Table
1). Surprisingly, compound 19 the phosphorylated (charged)
derivative of 14 showed an increase in the SPR response,
suggesting stabilization of the PDE6D/avi-K-RasFMe complex.
Direct target binding data were corroborated by a previously
published ﬂuorescence anisotropy (FA) assay, which detects
displacement of a ﬂuorescently labeled, farnesylated peptide
derived from the PDE6D client Rheb (F-Rheb)14 (Figure S1C,
Table S1).
Computational docking of Deltaﬂexin-1 into the PDE6D
crystal structure suggested that similar to the Deltasonamide
derivatives, the phosphotriester bottom moiety of Deltaﬂexin-1
forms hydrogen bonds with Arg61 and Gln78, at the base of the
PDE6D pocket (Figures 1D, S1D,E).16,17 In addition, the top-
moiety contacted Glu88, Ala112, and Met117. Therefore, three
out of the seven contacts that were also engaged by the most
optimized deltasonamide derivative (compound 817) were
utilized by Deltaﬂexin-1, consistent with the overall similar
positioning of the compound (Figure S1E). A comparison of
Deltaﬂexin-1 docked into PDE6D in the open and closed (Arl2-
bound) state illustrates that the potential steric clash between
the protected phosphodiester at the bottom of the pocket and
Arg61 would likewise persist (Figure 1D). However, the
presence of the adjacent ﬂexible hexyl linker may enable the
protected phosphodiester bottom moiety of Deltaﬂexin-1 to
evade this clash.
Deltaﬂexin-1 Disrupts K-Ras/PDE6D Interaction and
K-Ras Membrane Organization in Cells.Next, we tested for
on-target activity in cells, using a FRET-assay, which directly
detects the interaction between K-RasG12V and PDE6D.
Deltaﬂexin-1 signiﬁcantly reduced the FRET to a level
comparable to that of Deltarasin (Figure 2A). This activity
was also seen with three derivatives that employed diﬀerent
chemical coupling between top and linker moieties, suggesting a
notable degree of ﬂexibility for compound synthesis (Figure
S2A). By contrast, the control compound, 17, with a “stiﬀ”
methyl-cyclohexylmethyl linker moiety, lacked in cellulo activity
(Figure 2A), despite identical in vitro activity (Table 1).
Likewise, 14 and 19without the cell-penetration bottom-moiety
did not block the interaction (Figure 2A). In support of the
middle moiety requiring a speciﬁc length, shortening of the
methylen-linker to four carbons abrogated the inhibitory activity
in 20 (Figure 2A). Similar results were obtained using the
previously described FRET-pair of PDE6D and another client,
the farnesylated Ras-like GTPase Rheb (Figure S2B).11
PDE6D inhibition is expected to suppress K-Ras localization
and activity more than H-Ras.13 We therefore employed an
Table 1. Inhibitory Activities of Deltaﬂexins and Control
Compounds on Binding of PDE6D to avi-K-RasFMe as
Determined by SPR
inhibition of PDE6D/avi-K-RasFMe
compound IC50 ± SEM/μM Kd ± SEM/μM
Deltarasin 1.9 ± 0.1 1.4 ± 0.1
15 (Deltaﬂexin-1) 4.87 ± 0.03 3.61 ± 0.02
19 inconclusive
14 18.9 ± 0.2 14.1 ± 0.2
17 6.7 ± 0.1 4.97 ± 0.07
22 10.27 ± 0.03 7.62 ± 0.02
23 (Deltaﬂexin-2) 3.94 ± 0.03 2.92 ± 0.02
ACS Omega Article
DOI: 10.1021/acsomega.9b03639
ACS Omega XXXX, XXX, XXX−XXX
C
additional cellular FRET-assay that detects FRET due to
nanoscale clustering (nanoclustering-FRET) of Ras oligomers,
including dimers, on the membrane.21 We previously demon-
strated that nanoclustering-FRET can quantify subcellular
distribution changes that may be diﬃcult to establish by
confocal imaging (Figure S2C).22,23 Thus, we conﬁrmed that
FTI selectively aﬀects H-Ras membrane anchorage more than
that of K-Ras, as the latter can be alternatively prenylated by
geranylgeranyltransferase I2,24 (Figure 2B,C). Given that rate-
limiting steps of the PDE6D-mediated traﬃcking cycle
selectively facilitate plasma membrane anchorage of K-Ras,
but not H-Ras, knockdown of PDE6D selectively reduced the K-
Ras but not H-Ras nanoclustering-FRET (Figures 2B,C and
S2D). By contrast, the reference PDE6D-inhibitor, Deltarasin,
reduced FRET of both Ras isoforms about equally. This
indicates pan-Ras-directed, oﬀ-target eﬀects of Deltarasin that
may underlie its relatively high general toxicity.16 Deltaﬂexin-1
on the other hand selectively reduced K-RasG12V but not H-
RasG12V FRET as expected (Figure 2B,C). This was conﬁrmed
with the three linkage derivatives, further corroborating the
ﬂexibility at this position in our generic design (Figure S2E,F).
Importantly, Deltaﬂexin-1 demonstrated an in cellulo potency in
this FRET-assay [IC50(15) = 1.65± 0.95 μM (mean± standard
error of the mean (SEM))] that was comparable to the in vitro
aﬃnity (Kd = 3.61 ± 0.02 μM), although it was not as potent as
Deltarasin in cellulo [Figure 2D, IC50(Deltarasin) = 0.7 ± 0.4
μM (mean ± SEM)].
Previous work suggested that the pharmacological stability of
the cell penetration group can be tuned within the esterase
cleavable S-acyl moiety by the electronegativity of the 2-
substituent, such as ethoxycarbonyl (relatively labile) or methyl
(more stable).20 Indeed, heating of Deltaﬂexin-1 before
application to cells decreased its cellular activity to a level
similar to that of 14 or 19, which both do not have the cell
penetration group (Figure S2G).
In conclusion, these results demonstrate that the hexyl-spring
and cell penetration group enable a similar in cellulo potency of
Deltaﬂexin-1 as observed in vitro. Importantly, Deltaﬂexin-1 acts
on-target in cells allowing for a selective inhibition of K-Ras
activity, whereas the reference compound Deltarasin aﬀects
equally K-Ras and H-Ras.
Deltaﬂexin-1 Selectively Inhibits Oncogenic K-Ras
Driven Cell Proliferation and Tumorosphere Formation.
In order to further validate the K-Ras selectivity in cells, we
examined the eﬀect of Deltaﬂexin-1 and derivatives on 2D
proliferation of colorectal cancer cell lines. Deltaﬂexin-1
inhibited the K-RasG13D mutated HCT116 (IC50 = 11 μM,
CI 95% 8.1−16 μM) signiﬁcantly more than the Ras wt HT-29
cell line (IC50 = 40 μM, CI 95% CI 25−72 μM, p < 0.0001)
(Figure 3A,B). Similar micromolar activities and oncogenic K-
Ras selectivity (p < 0.0001) were also seen in the K-RasG13D-
mutated and -dependentMDA-MB-231 (IC50 = 7.2 μM,CI 95%
5.1−9.7 μM) and H-RasG12D-mutated and -dependent Hs
578T (IC50 = 21 μM,CI 95% 13−35 μM)breast cancer cell lines
(Figure S3A,B,G). Both activity and K-Ras selectivity in colon
and breast cancer cells were corroborated by Deltaﬂexin-1
linkage derivatives (Figure S3C−F).
Thus, half-maximal inhibition of K-Ras-mutant cancer cell
viability by Deltaﬂexin-1 occurred at approximately 7- to 11-fold
higher concentrations than in the cellular K-Ras nanoclustering-
FRET assay, which also means that the in vitro and cancer cell
inhibitory activities were very similar. By contrast, the diﬀerence
between cellular inhibition and in cellulo on-target activity of the
bis-sulfonamide inhibitor Deltasonamide 2 was 12- to 25-fold,
while an even greater diﬀerence is apparent for this compound
when compared to the in vitro aﬃnity (650- to 1300-fold).17 It is
plausible to assume that the better in vitro/cell inhibition
activity relation of Deltaﬂexin-1 compared to Deltasonamide 2 is
due to its spring moiety.
While these results demonstrate selectivity for cancer cells
expressing mutant K-Ras, the comparison of proliferation in 2D
is not as discriminatory as the nanoclustering-FRET assay.
However, in the past, we established that compounds which
selectively decrease K-Ras-, but not H-Ras-nanoclustering-
FRET, have a high potential as inhibitors of stemness properties
of cancer cells, as measured by the formation of tumoro-
spheres.22,25 Accordingly, the selective eﬀect of PDE6D on K-
Ras but not H-Ras (Figure 2B,C)makes PDE6D a good target to
enable such anticancer stemness activity. Indeed, tumorosphere
formation of K-RasG12V, but not H-RasG12V transfected or
control HEK cells,26 was selectively decreased after knockdown
of PDE6D (Figure S3H−J). Similarly, mammospheres derived
from K-Ras mutant MDA-MB-231 were inhibited by Delta-
Figure 2. Deltaﬂexin-1 inhibits K-Ras/PDE6D interaction and selectively disrupts K-Ras membrane organization (A) PDE6D/K-Ras interaction by
FLIM-FRET. HEK cells were co-transfected with mGFP tagged K-RasG12V and mCherry tagged PDE6D. Transfected cells were treated with 0.1%
dimethyl sulfoxide (DMSO) control or 5 μMDeltaﬂexin-1, 17, 14, Deltarasin, or 500 nM FTI-277 for 24 h; n = 3. (B,C) Ras membrane organization
measured with nanoclustering-FRET in HEK cells coexpressing mGFP or mCherry tagged K-RasG12V (B) or mGFP or mCherry tagged H-RasG12V
(C). Cells were cotransfected with siRNA-PDE6D for 48 h or treated with 0.1%DMSO control, 5 μMDeltaﬂexin-1, 17, 14, Deltarasin, or 0.2 μMFTI-
277 for 24 h; n = 3. (D) K-Ras nanoclustering-FRET dose response curve of Deltaﬂexin-1 or Deltarasin. Cells were treated for 24 h; n = 3. The numbers
on the bars indicate numbers of analyzed cells. Graphs showmean values± SEM. Statistical signiﬁcance levels are annotated as ****p < 0.0001; ns, not
signiﬁcant.
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ﬂexin-1 more signiﬁcantly than those of H-Ras mutant Hs 578T
(Figure 3C−F). Control compounds 17 and 20 with a stiﬀ or
shortened linker, respectively, had no signiﬁcant eﬀect (Figure
3C,D). This K-Ras-mutant mammosphere selectivity was largely
conﬁrmed with the Deltaﬂexin-1 linkage derivatives (Figure
S3K,L), nevertheless suggesting some oﬀ-target eﬀects on
tumorosphere growth by the diﬀerent linkages.
Second Generation Deltaﬂexins with Improved Che-
motype. Encouraged by these results, a second generation of
inhibitors was developed based on Deltaﬂexin-1. We replaced
the potentially toxic coumarin moiety with a substituted
terephthalic acid moiety, thus generating a partial hybrid with
a bis-sulfonamide Deltasonamide inhibitor (compound 817)
(Figure 4A). In addition, the bottom moiety was varied to
characterize the activity of the pharmacologically more stable 2-
methyl-substituent on the S-acyl cell penetration group. While
compound 23 with the more stable bottom-moiety had a
comparable aﬃnity to 15, its analogue 22 bound with a 2.6-fold
lower aﬃnity (Figure 4B, Table 1, Figure S4A, Table S1).
Computational docking supported these data, as overall
similar positioning and similar contacts as for Deltaﬂexin-1 were
observed for the second-generation compounds in the PDE6D
pocket (Figure S4B). It appeared though that the substitution of
the top moiety from an aromatic two-ring system to one
aromatic ring allowed for more ﬂexibility of the top moiety
orientation. Moreover, the potential for a new hydrogen bond
with Ser115 was identiﬁed for both 22 and 23. In addition, the
bending of 23 could contribute to the formation of an additional
hydrogen bond with Glu88, which is not observed in 22 (Figure
S4B). The relative strength of these interactions may contribute
to the observed diﬀerences in the binding aﬃnities.
In agreement with the in vitro data, second-generation
compound 23 performed as well as 15 and somewhat better than
22 in disrupting the K-RasG12V/PDE6D interaction as assessed
by FRET-experiments in cells (Figure 4C). Similarly, amongst
the 4n-methylen-linker counterparts of 22 and 23, 25 performed
better than 24 (Figure 4A,C). These data further support that
the replacement of the relatively labile 2-ethoxycarbonyl with
the more stable 2-methyl on the S-acyl cell penetration group is
beneﬁcial. Finally, 22 and 23 (hereafter named Deltaﬂexin-2)
led to a signiﬁcant dose-dependent reduction of the K-RasG12V
nanoclustering-FRET compared with 24 and 25 (Figure 4D).
No eﬀect on H-RasG12V FRET was observed (Figure S4C).
Recently, exquisite K-RasG12C selectivity was demonstrated
for the covalent inhibitor ARS-1620.7 In agreement with a
signiﬁcant overall activity, quantitative scoring of the chemical
inhibition of PDE6D with Deltaﬂexin-2 revealed that it had 70%
activity of ARS-1620 in KRAS-G12C mutant NCI-H358 lung
cancer cells grown as tumorospheres. Moreover, Deltaﬂexin-2
was inactive in the B-RafV600E mutant A375 lung metastasis
melanoma cell line, as was ARS-1620 (Figure 4E). These data
conﬁrm that Deltaﬂexins signiﬁcantly inhibit cell spheroid
growth in a K-Ras selective manner. By contrast, no such
selectivity was found for Deltarasin, which showed equally high
activity in both cell lines, again suggesting a general oﬀ-target
toxicity.
Similarly, K-RasG13D-mutant MDA-MB-231- but not H-
RasG12V-mutant Hs 578T-mammosphere formation was
selectively decreased by Deltaﬂxin-2, while the counterpart
with the shorter ﬂexible linker 25 was inactive (Figure S4D,E).
In line with the Ras-mutation status, the mammosphere
formation of MDA-MB-231 and Hs 578T was selectively
abrogated by the knockdown only of the mutated Ras isoform
(Figure S4F−I), conﬁrming that this assay can report on the
selectivity for oncogenic K-Ras (MDA-MB-231) or H-Ras (Hs
578T). However, knockdown of PDE6D strongly aﬀected
sphere formation of both cell lines (Figure S4F,G).
We therefore conclude that Deltaﬂexins can block stemness
traits of cancer cells and have a clear in cellulo selectivity for K-
Ras as compared to H-Ras. However, our data also suggest that
the stemness inhibiting activity of PDE6D inhibitors depends at
least in breast cancer cell lines on other clients or activities of
PDE6D.
In this work, we have demonstrated that the attachment of a
“chemical spring” and cell penetration group to a generic
heterocycle enables the de novo design of low micromolar
PDE6D inhibitors in the ﬁrst generation. This redesign
approach is strikingly simple and together with the ﬂexible
Figure 3. Deltaﬂexin-1 selectively inhibits oncogenic K-Ras-driven cell
proliferation and mammosphere formation. (A,B) Dose-dependent cell
viability in response to 72 h treatment with Deltaﬂexin-1 at
concentrations ranging from 0 to 20 μM in HCT116 cells (A) and
HT-29 cells (B). Graphs showmean values± SEM, n = 4. (C,D) Sphere
formation eﬃciency (SFE) of MDA-MB-231 cells (C), n = 11, and Hs
578T cells (D), n = 7, cultured in suspension culture for 6 days,
followed by a 72 h incubation with 5 μMDeltaﬂexin-1 or Deltarasin, 0.5
μMFTI or 0.1%DMSO control. Graphs showmean values± SEM. (E)
Deltaﬂexin-1 dose-dependent eﬀect on SFE with the same protocol as
in (C,D). Graphs show mean values ± SEM, n = 4. The SFE is
signiﬁcantly diﬀerent between MDA-MB-231 and Hs 578T above 0.63
μM. (C−E) Statistical signiﬁcance levels are annotated as ns, not
signiﬁcant; *p < 0.05; **p < 0.01; ****p < 0.0001; ns, not signiﬁcant.
(F) Representative images of MDA-MB-231 and Hs 578T spheroids at
day 10 of suspension culture, after indicated treatments as in (C,D).
Scale bar of 200 μm is representative for all images.
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coupling chemistry should allow for improvements of existing
PDE6D inhibitors. As validated by the second-generation
compounds, our approach is compatible with compound-
scaﬀold hybridization of existing PDE6D compounds. Thus,
we expect to quickly advance the development of more potent
derivatives in the near future. Moreover, our strategy may apply
to inhibitors of closely related targets, such as UNC119,27 in
addition to PDE6D inhibitors.
Past generations of PDE6D inhibitors underwent substantial
structure-based optimization to arrive at sub and low nanomolar
in vitro activities, but surprisingly they exhibited∼1000-fold less
antiproliferative potential in cancer cells. Thus, the relation of
Figure 4. Partial scaﬀold hybridization creates second-generation inhibitors. (A) Second-generation compounds have an altered “top” moiety taken
from a previously published PDE6D inhibitor. Note the variation of the protecting group between 22 and 23, as well as 24 and 25. Linker length is
varied between the 22, 23 vs 24, 25. (B) SPR data of avi-K-RasFMe/PDE6D treated with 22 and 23 (Deltaﬂexin-2) and dose response curves
constructed from SPR kinetic data; n = 3. (C) PDE6D/K-Ras interaction by FLIM-FRET. HEK cells were cotransfected with mGFP-tagged K-
RasG12V and mCherry-tagged PDE6D. Transfected cells were treated with 0.1% DMSO control or 5 μM (n = 3) and 10 μM (n = 1) compounds 22,
23, 24, 25, or 5 μM Deltaﬂexin-1, Deltarasin for 24 h;. (D) K-Ras membrane organization measured with nanoclustering-FRET in HEK cells
coexpressing mGFP or mCherry tagged K-RasG12V for 48 h or treated with 0.1% DMSO control, and various concentrations of compounds 22, 23,
24, 25, or 5 μMDeltaﬂexin-1, Deltarasin for 24 h; n = 3. For all FRET-data, the numbers on the bars indicate the number of analyzed cells. (E) Dose-
dependent cell viability of lung cancer cell lines, NCI-H358 and A375 grown as spheroids under low attachment and serum free conditions in response
to 72 h treatment with ARS-1620, Vemurafenib, FTI-277, Deltarasin, Deltaﬂexin-1, andDeltaﬂexin-2 at concentrations ranging from 0 to 20 μM; n≥ 3.
Higher eﬃcacy results in a higher drug sensitivity score (DSS), an area under the curve (AUC) metric. Graphs show mean values ± SEM. Statistical
signiﬁcance levels are annotated as **p < 0.01; ****p < 0.0001; ns, not signiﬁcant.
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Deltaﬂexin-2 in vitro and in cellulo potencies is ∼60- to 180-
times better than that of Deltasonamide-2. Moreover, as
compared to Deltarasin, Deltaﬂexins demonstrated the expected
selectivity for K-Ras over H-Ras in cells. Therefore, the current
Deltaﬂexins can serve as valuable tool compounds to investigate
the PDE6D associated anticancer mechanisms. While we
demonstrate the K-Ras selectivity of Deltaﬂexins, the compar-
ison of PDE6D- and KRAS-knockdown data suggests K-Ras-
independent eﬀects of PDE6D inactivation on stemness traits of
cancer cells. Other activities of PDE6D or clients other than K-
Ras could be important in this context. For example, the PDE6D
client INPP5E (inositol polyphosphate-5-phosphatase E) local-
izes to the primary cilium in a PDE6D-dependent manner.28−30
In line with a potential contribution of INPP5E inhibition to the
antistemness eﬀect, primary ciliogenesis and associated Hedge-
hog signaling have recently been linked to epithelial−
mesenchymal transition and stemness promotion in triple
negative breast cancer.31
Nonetheless, K-Ras overactivity appears to be an important
biomarker for the eﬃcacy of PDE6D inhibitors.32 In order to
establish the exact therapeutic spectrum of the single-agents, a
broader panel of cancer cells should be tested with PDE6D
inhibitors in the future. Given that carboxymethylation of the
prenylated C-termini of small GTPase clients provides addi-
tional aﬃnity, it is foreseeable that concurrent inhibition of
isoprenylcysteine carboxyl methyltransferase, by inhibitors such
as cysmethynil, will be synergistic with PDE6D inhibitors.12,32
While targeting of signaling or traﬃcking hubs, such as
PDE6D, could intuitively lead to more side eﬀects, this approach
may in the end be advantageous from the drug development
point of view. Given that diﬀerent cancer types and subtypes
have diverse sets of drivers,33,34 drugs that target a hub may
aﬀect several cancer drivers at once. Such hub inhibitors may
therefore be more easily applicable to several types of cancer.
This strategy is, for example, pursued for inhibitors of Hsp90,
which is a major hub of kinases.35,36 Irrespective of their exact
mechanism of action, PDE6D inhibitors therefore remain
attractive as potential cancer drugs.
■ METHODS
DNA Constructs and siRNA. Plasmids pmGFP/mCherry-
H-RasG12V and pmGFP/mCherry-K-RasG12V were previ-
ously described.22,23 Plasmids for mCit-Rheb and mCherry-
PDE6D were previously described.11 The human gene-directed
siRNAs were purchased fromDharmacon as ON-TARGET plus
SMART siRNA pools. The catalogue numbers are as follows:
scrambled siRNA (cat. no. D-001810-10-05), human KRAS
(cat. no. L-005069-00, lot 170710), human HRAS (cat. no. L-
004142-00, lot 160414), and human PDE6D (cat. no. L-
004310-00). Opti-MEM and transfection reagents Lipofect-
amine 3000 (cat. no. L3000001) and RNAiMAX (cat. no.
13778030) were purchased from Thermo Fisher Scientiﬁc.
JetPrime (cat. no. 114-75) was obtained from Polyplus, Illkrich-
Graﬀenstaden, France. FuGENE HD (cat. no. E2311) was
purchased from Promega Biotech AB, Nacka, Sweden.
Cell Culture. HEK293 EBNA cells were kind gift of Prof.
FlorianMWurm, EPFL, Lausanne, Switzerland. MDA-MB-231,
Hs 578T, HCT116, HT-29, NCI-H358, and A-375 cell lines
were obtained from ATCC. HEK293 EBNA, Hs 578T,
HCT116, and HT-29 cell lines were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM, cat. no. D6171, Sigma-
Aldrich, Helsinki, Finland), supplemented with 10% fetal bovine
serum (FBS) (cat. no. S1810, Biowest, Nuaille, France) and 2
mM L-glutamine (cat. no. G7513, Sigma-Aldrich). MDA-MB-
231, NCI-H358, and A375 cells were cultured in Roswell Park
Memorial Institute medium (RPMI, cat. no. R5886, Sigma-
Aldrich), containing 10% FBS and 2 mM L-glutamine. All cells
were incubated at 37 °C, with 5% CO2, in a humidiﬁed cell
incubator. Cells were subcultured twice a week.
Fluorescence Lifetime Imaging Microscopy-FRET.
HEK293 EBNA cells were seeded in 12-well plates onto sterile
coverslips. The next day, cells were transfected using FuGENE
HD or jetPRIME transfection reagent with a total of 800 ng of
plasmids. For donor samples, cells were transfected with mGFP
or mCitrine-tagged plasmid. In FRET pairs, donors and
acceptors were transfected at a 1:3 ratio. Acceptors were
mCherry-tagged Ras plasmids in the nanoclustering-FRET
experiments for membrane organization studies. For interaction
studies, pmGFP-K-RasG12V and pmCherry-PDE6D, or pmCi-
trine-Rheb and pmCherry-PDE6D, were used all at the same 1:3
ratios with a total of 800 ng plasmids being used in each
experiment. After 24 h of transfection, cells were treated with
either 0.1% DMSO control or various concentrations of test
compound or Deltarasin (cat. no. 9001536, Cayman Chemical,
Tallinn, Estonia), or FTI-277 (cat. no. Sc-215058, Santa Cruz
Biotechnology, Dallas, USA) or FTI-2628 (cat. no. sc-221635,
Santa Cruz Biotechnology) for 24 h and ﬁxed in 4%
paraformaldehyde (PFA) before mounting with Mowiol 4-88
(cat. no. 81381, Sigma-Aldrich). The donor ﬂuorescence
lifetime was measured using a ﬂuorescence microscope (Zeiss
AXIO Observer D1) with a ﬂuorescence lifetime imaging
attachment (Lambert Instruments, Groningen, The Nether-
lands), as previously described in refs 37, 38. The ﬂuorescence
lifetime of at least 40 cells per treatment was measured in each
experiment. The percentage of the apparent FRET eﬃciency
(Eapp) was determined using the measured lifetimes of donor−
acceptor pairs (τDA) of samples and the average donor lifetime
(τD), based on the equation: Eapp= (1 − τDA/τD) × 100%.
Tumorosphere Assays. Mammosphere formation assays
were performed in F-bottom 96-well suspension culture plates
(cat. no. 655185, Cellstar, Greiner Bio-One, Frickenhausen,
Germany). 1500 cells per well were seeded in 50 μL DMEM or
RPMI medium containing 1× B27 (cat. no. 17504044, Gibco,
Thermo Fisher Scientiﬁc), 25 ng/mL EGF (cat. no. E9644,
Sigma-Aldrich), and 25 ng/mL FGF (cat. no. RP-8628, Thermo
Fisher Scientiﬁc). Cells were cultured for 6 days and then treated
with test compounds or DMSO control (0.1% v/v) for
additional 3 days. The cells were resupplemented with fresh
growth medium every 2 days. For knockdown experiments and
for K-Ras and H-Ras transfections, cells were seeded in 6-well
plates and treated with either 50 nM scrambled siRNA or siRNA
targeting PDE6DKRAS orHRAS or withmGFP-K-RasG12V or
mGFP-H-RasG12V plasmids, using jetPRIME transfection
reagent or Lipofectamine 3000. On the next day, cells were
replated into 96-well plates for suspension cell culture.
Mammosphere formation was analyzed under an EVOS FL
microscope (Thermo Fisher Scientiﬁc) and spheres exceeding
50 μm in diameter were counted. The SFE was expressed as
percentage normalized to vehicle-treated control. In protein
overexpression or knockdown experiments, SFE was normalized
to the empty vector or scrambled siRNA-transfected controls,
respectively.
Tumorospheres of lung cancer cells were generated by
seeding NCI-H358 or A-375 cells (1500 cells per well) as a
suspension culture in F-bottom 96-well suspension culture
plates (cat. no. 655185, Cellstar, Greiner Bio-One) in 50 μL
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RPMImedium supplemented with 0.5%methylcellulose, 25 ng/
mL EGF, 25 ng/mL FGF, 1× B-27 supplement, and 2 mM L-
glutamine. Cells were initially grown for 72 h and treated with
freshly thawed compounds. After another 72 h of incubation, the
cell viability was assessed using the alamarBlue assay (cat. no.
DAL1100, Invitrogen, Carlsbad, CA, USA). A 10% ﬁnal volume
of alamarBlue reagent was added to each well of the plate and
incubated for 4 h at 37 °C. Then, the ﬂuorescence intensity was
measured using a FLUOstar OPTIMA plate reader (BMG
Labtech, Germany) with an excitation wavelength of 560± 5 nm
and emission wavelength of 590 ± 5 nm. The obtained
ﬂuorescence intensity data were normalized to DMSO control.
To quantitatively proﬁle the drug sensitivity from the dose−
response data, the DSS algorithm was employed.39 The DSS
score was calculated according to the formula
a
DSS
100 AUC
TA log
= ×
×
The curve ﬁtting parameters were used to calculate the AUC
relative to the total area (TA) between the 10% threshold
(DMSO at 0.1%) and 100% inhibition (benzethonium chloride
at 100 μM). The integrated response is divided by the logarithm
of the top asymptote (log a).
2D Cell Viability Assay. Hs 578T, HCT-116, and HT29
cells were plated onto 96-well cell culture plates at a density of
500 cells/well and allowed to attach for 24 h. Freshly thawed
aliquots of test compounds were then added ice-cold at
indicated concentrations. DMSO (0.1% v/v) was used as
control. Plates were further incubated for 72 h. The cell viability
was assessed using the alamarBlue reagent, according to
manufacturer’s instructions. The ﬂuorescence intensity was
read with the excitation wavelength of 530 ± 10 nm and
emission wavelength of 590 ± 10 nm using a Synergy H1 plate
reader (BioTek, Winooski, VT, USA).
Western Blotting. Cells were lysed in RIPA buﬀer (cat. no.
89900, Thermo Scientiﬁc) containing protease (cat. no. 88666,
Thermo Scientiﬁc) and phosphatase inhibitors (cat. no.
0496845001, Roche, Mannheim, Germany) and then sonicated
for 5 min in ice-cold water. Proteins were separated on 10%
sodium dodecyl sulfate polyAcrylamide gel electrophoresis
(SDS-PAGE) gels and transferred to nitrocellulose membranes
(cat. no. NBA 083C001EA, Protran, Waltham, USA) using a
Transferblot Turbo Transfer System (Bio-Rad, Hercules, CA,
USA). Brieﬂy, the membranes were blocked in 1xTBS
containing 0.1% Tween-20 and 5% w/v nonfat dry milk for 30
min and incubated with primary antibodies PDE6D (cat. no. sc-
166854, Santa Cruz Biotechnology, Paso Robles, CA, USA.) or
β-actin (cat. no. A1978, Sigma-Aldrich) overnight, at 4 °C. The
membranes were then incubated with secondary antibodies
antimouse (cat. no. sc-2954, Santa Cruz Biotechnology) for 1 h
at room temperature. Protein bands were detected using a
ChemiDoc MP instrument (Bio-Rad) after treatment with ECL
reagent (cat. no. 170-5061, BioRad). The protein-band
intensities were measured using Image Lab software (Bio-Rad).
RT-qPCR Analysis for Gene Knockdowns. MDA-MB-
231 and Hs 578T cells were seeded in 6-well plates and
transfected with 50 nM of siRNA KRAS or HRAS or scrambled,
negative control siRNA (QIAGEN, cat. no. 1022076, QIAGEN,
Hilden, Germany) using Lipofectamine. After 24 h of trans-
fection, total RNA was isolated using NucleoZol according to
the manufacturer’s protocol (cat. no.: 7040404, Macherey-
Nagel, Hoerdt, France). Reverse transcription was performed
with 1 μg of total RNA using SuperScript III Reverse
Transcriptase (cat. no.: 18080093, Invitrogen). The knock-
downs of KRAS and HRAS gene transcripts were analyzed by
real-time qPCR using SsoAdvanced Universal SYBR Green
Supermix (Bio-Rad), on the CFX-connect real-time PCR
instrument (Bio-Rad). The transcripts were selectively ampliﬁed
using speciﬁc primers producing amplicons for KRAS (total)
and HRAS. The gene β-actin was used as reference. The
following primers were used: for KRAS (total), forward 5′-
tacagtgcaatgagggacca-3′, reverse 5′-tcctgagcctgttttgtgtct-3′ (am-
plicon 206 bp); for HRAS, forward 5′-ctgaccatccagctgatcca-3′,
reverse 5′-tggcaaacacacacaggaag-3′ (amplicon 196 bp); for
ACTB (β-actin), forward 5′-ggggtgttgaaggtctcaaa-3’; reverse 5′-
ggcatcctcaccctgaagta-3′.40
Confocal Imaging. MDCK cells, stably overexpressing
mGFP-KRasG12V, were seeded onto coverslips in 12-well cell
culture plates. The cells were treated with 0.1% DMSO control
or 5 μMDeltarasin or Deltaﬂexin-1. After 24 h cells were ﬁxed in
4% PFA and mounted with Mowiol, cells were imaged using a
laser scanning microscope (LSM 780) Carl Zeiss Microscopy,
Jena, Germany.
Compound Syntheses. Purchased compounds were used
without further puriﬁcations. Chemicals and solvents were
purchased from the companies Sigma-Aldrich, VWR, and
Thermo Fisher Scientiﬁc. Solvents were dried over 3 or 4 Å
molecular sieves. Commercially available solvents for semi-
preparative high-performance liquid chromatography (HPLC)
(acetonitrile HPLC grade) were used. Solvent mixtures are
understood as volume/volume. Extended information on the
complete compound syntheses and analytics are described in
Supporting Information S1.
Molecular Modeling. Docking studies were carried out by
the GOLDmodule41 of Discovery Studio 4.5 (Accelrys Inc. San
Diego, USA, http://www.accelrys.com/) using the crystal
structure of PDE6D determined at 1.45 Å resolution (PDB
code 4JV8)15 as the receptor molecule. Water molecules and the
bound ligand were removed from the structure prior to the
docking. Binding sites were identiﬁed by using the binding site
identiﬁcation tool in Discovery Studio. The binding site that
matched also the binding site identiﬁed by the crystal structure
was selected for docking. The ligands were generated with
ChemDraw Professional 15.1 (PerkinElmer Informatics, www.
cambridgesoft.com) and exported as *.mol ﬁles to the Discovery
Studio. Hydrogen atoms were added to the protein and the
ligand. The Goldscore ﬁtness function was used to score the
poses.
SPR Binding and Inhibition Assays. SPR binding
experiments were performed on a Biacore S200 instrument
(GE Healthcare Life Sciences, Marlborough, MA, USA) as
described previously.42 Farnesylated and methylated K-Ras-
GDP (K-RasFMe), with an N-terminal avi-tag, was captured on
neutravidin-coupled CM5 sensor chips (capture density 500−
1500 RU). PDE6D (2-fold serial dilution, 20−0.039 μM) was
injected over the K-RasFMe surface in 20 mM N-(2-
hydroxyethyl)piperazine-N′-ethanesulfonic acid (HEPES)
(pH 7.5), 150 mM NaCl, 0.01%, Tween 20, 5 mM MgCl2,
and 5% DMSO at 30 μL/min and with a contact time of 60 s.
The inhibitory activity of compounds for PDE6D/K-RasFMe
interaction was measured using 1.25 μM PDE6D and a serial
dilution of compound (2-fold, 100−0.39 μM) using the same
buﬀer and ﬂow rate. PDE6D (1.25 μM) was diluted with
Deltarasin (3-fold, 50 μM to 68 nM) was used as a positive
control. All titrations were run over three ﬂow cells with variable
surface densities of K-RasFMe. The data were processed by
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subtracting binding responses on the reference ﬂow cells as well
as the buﬀer subtraction. The samples were also corrected for
DMSO mismatches using a DMSO standard curve. The
equilibrium binding constant and IC50 values were calculated
using the Biacore S200 Evaluation software. The IC50 value
obtained from SPR and FA assay was converted into Kd using a
modiﬁed Cheng−Prusoﬀ equation
K
IC
1 L
K
d
50
D
=
+ [ ]
where KD is the dissociation constant between PDE6D/K-
RasFMe and [L] is the concentration of PDE6D used in SPR
experiments.44
FA Assay. The binding of compounds to PDE6D was
assessed in an FA assay using ﬂuorescein-tagged farnesylated
Rheb (F-Rheb) peptide as the probe.14,43 PDE6D was produced
as described below. FA assays were performed on a black low
volume, round-bottom, non-binding surface 384-well plate
(Corning, #4514) in an assay buﬀer composed of 30 mM Tris,
150mMNaCl, and 3mMdithiothreitol. To a three-fold dilution
of compounds in assay buﬀer (300 μM to 1.7 nM), a complex of
0.25 μM F-Rheb peptide and 2 μM PDE6D was added, and the
reaction mix was incubated for 15 min at RT. Then, the FP was
recorded on a Synergy H1 hybrid plate reader (BioTek)
equipped with a polarization cube with an excitation wavelength
of 485 ± 10 nm and emission wavelength of 528 ± 10 nm. The
FP data were plotted against the logarithmic concentration of
compounds and ﬁt to log inhibitor vs response−variable slope
(four parameters) equation in Prism (GraphPad), and the IC50
was determined.
Cloning, Expression, and Puriﬁcation of Recombinant
Proteins. PDE6D was recombinantly produced in Escherichia
coli BL21 (DE3) transformed with pDest-His6-MBP-PDE6D
grown at 37 °C until OD of 0.6−0.8 and then induced with 0.5
mM of β-D-1-thiogalactopyranoside overnight at 16 °C.12 The
bacterial lysate was prepared in a binding buﬀer (20 mM
HEPES, pH 7.6, 300 mM NaCl, 5 mM MgCl2, 1 mM TCEP
(Tris(2-carboxyethyl)phosphine hydrochloride), and protease
inhibitor tablet fromRoche) containing 0.5mg/mL of lysozyme.
Soluble proteins were isolated after sonication and centrifuga-
tion steps. The protein His6-MBP-TEV-PDE6Dwas puriﬁed on
HisTrap HP column (GE Healthcare) in binding buﬀer
containing imidazole and eluted with a 20 column-volume
gradient from 35 to 500 mM imidazole. The eluted fractions
were analyzed on SDS-PAGE. The fractions containing His6-
MBP-TEV-PDE6D were treated with tobacco etch virus (TEV)
protease (cat. no.: T4455, Sigma-Aldrich) (1:25 w/w, TEV/
fusion protein) for 1 h at room temperature and then dialyzed
overnight in binding buﬀer without protease inhibitor. The
cleavage product containing His6-MBP and PDE6D was loaded
a second time on a HisTrap HP column in binding buﬀer. The
peak fractions (OD280) corresponding to the nonbound
protein PDE6D were collected, pooled, concentrated using
Amicon Ultra Centrifugal Filters (Merck Millipore, Molsheim,
France), and analyzed on a SDS-PAGE gel with Coomassie blue.
The presence of puriﬁed PDE6D was conﬁrmed by Western
blotting using a monoclonal anti-PDE6D antibody (cat. no.: sc-
376724, Santa Cruz Biotechnology; dilution ratio 1:200).
The baculovirus expression vector for production of
processed K-Ras4B has been previously described.44 An avi-
tagged full-length K-Ras4B clone was generated by introducing
an avi sequence (LNDIFEAQKIEWG) between the TEV
protease cleavage site (ENLYFQG) sequence and amino acids
2−188 of K-Ras4B. The baculovirus expression vector for the
production of processed avi-K-Ras4B was produced using the
methods described previously.44 Expression of farnesylated and
carboxymethylated K-Ras4B (K-RasFMe) and avi-K-Ras-FMe
followed the methods as described.42 Puriﬁcation of processed
avi-tagged full-length K-Ras4B was as described44 with
modiﬁcations. Protein isolated after the removal of the N-
terminal His6-MBP tag (21.5 μM avi-K-Ras-FMe) was
biotinylated by incubating for 2 h at room temperature with
2.8 μMHis6-BirA, 3.6 mMATP, 215 μMbiotin in a buﬀer of 20
mMHEPES, pH 7.3, 300mMNaCl, 5 mMMgCl2, 1 mMTCEP
(Tris(2-carboxyethyl)phosphine hydrochloride), and 1:1000 v/
v protease inhibitor (P8849 Sigma-Aldrich). The reaction was
then dialyzed at 4 °C for 16 h against 20 mM HEPES, pH 7.3,
300 mM NaCl, 5 mM MgCl2, and 1 mM TCEP. The dialyzed
reaction was passed over a HisTrap FF column (GE Health-
care), equilibrated with dialysis buﬀer, to remove His6-BirA.
The biotinylated avi-K-Ras-FMe has a slight aﬃnity for the
column and elutes from the column at low (<50 mM) imidazole
concentrations. Fractions were analyzed by coomassie-stained
SDS-PAGE, and positive fractions were pooled and dialyzed
against 20 mM HEPES, pH 7.3, 300 mM NaCl, 1 mM MgCl2,
and 1 mM TCEP for 3 h at room temperature. The protein
concentration was determined by absorbance at 280 nm, and
aliquots were snap frozen in liquid nitrogen and stored at −80
°C.
Statistical Analysis. GraphPad Prism software was used for
the statistical analysis. The sample size n for each data set is
provided in the relevant ﬁgure legends and represents
independent experiments. Unless otherwise stated, statistical
signiﬁcance was evaluated with the Student’s t-test or One-way
ANOVA complemented by multiple comparison post hoc tests,
as appropriate. A p-value of <0.05 is considered statistically
signiﬁcant, and the statistical signiﬁcance levels are annotated as
* = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001,
or ns = not signiﬁcant.
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Chinnaiyan, A. M. Integrative Clinical Genomics of Metastatic Cancer.
Nature 2017, 548, 297−303.
(34) Garraway, L. A.; Lander, E. S. Lessons From the Cancer Genome.
Cell 2013, 153, 17−37.
(35) Butler, L. M.; Ferraldeschi, R.; Armstrong, H. K.; Centenera, M.
M.; Workman, P. Maximizing the Therapeutic Potential of HSP90
Inhibitors. Mol. Cancer Res. 2015, 13, 1445−1451.
(36) Taipale, M.; Krykbaeva, I.; Koeva, M.; Kayatekin, C.; Westover,
K. D.; Karras, G. I.; Lindquist, S. Quantitative Analysis of Hsp90-Client
Interactions Reveals Principles of Substrate Recognition. Cell 2012,
150, 987−1001.
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